DALLAS and FORT WORTH, Texas, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a fully
integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR)
products using its proprietary modified-release drug delivery technologies, today announced that Jerry McLaughlin, Chief Executive
Officer of Neos Therapeutics, will present a company overview at the upcoming 2018 Cantor Global Healthcare Conference on
Wednesday, October 3, 2018 at 2:50 p.m. ET in New York, NY.
A live webcast of the presentation will be available on the Investor Relations page of the company’s website at
http://investors.neostx.com/. Following the presentation, a replay of the webcast will be
available on Neos’ website for 30 days.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and
commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT®
(amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT™ (methylphenidate)
extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER™ (amphetamine)
extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the
first three approved products using the Company’s extended-release technology platform. In addition, Neos manufactures and
markets its generic version of the branded product Tussionex®1, an extended-release oral suspension of hydrocodone and
chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold (see Full Prescribing Information, including Boxed WARNING). Additional information about Neos is
available at www.neostx.com.
1Tussionex® is a registered trademark of the UCB Group of Companies.
Contacts:
Richard Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
Sarah McCabe
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com
